The human cathelicidin peptide LL-37 inhibits pancreatic cancer growth by suppressing autophagy and reprogramming of the tumor immune microenvironment

The human cathelicidin peptide LL-37 inhibits pancreatic cancer growth by suppressing autophagy and reprogramming of the tumor immune microenvironment

Pancreatic cancer is amongst the most lethal malignancies, while its poor prognosis could be associated with promotion of autophagy and the tumor immune microenvironment. Studies have confirmed the pro-tumorigenic nature of the cathelicidin family of peptide LL-37 in several types of cancer. However...

Full description

Bibliographic Details
Main Authors:	Zhu Zhang, Wen-Qing Chen, Shi-Qing Zhang, Jing-Xuan Bai, Ching-Lam Lau, Stephen Cho-Wing Sze, Ken Kin-Lam Yung, Joshua Ka-Shun Ko
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-07-01
Series:	Frontiers in Pharmacology
Subjects:	pancreatic cancer LL-37 autophagy ROS mTOR signaling tumor immune microenvironment
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.906625/full

Similar Items

Role of antimicrobial peptide cathelicidin in thrombosis and thromboinflammation
by: Qing Zhang, et al.
Published: (2023-04-01)

Efficacy of Cathelicidin LL-37 in an MRSA Wound Infection Mouse Model
by: Oriana Simonetti, et al.
Published: (2021-10-01)

Renovation as innovation: Repurposing human antibacterial peptide LL-37 for cancer therapy
by: Fatai Lu, et al.
Published: (2022-08-01)

Serum LL‐37 and inflammatory cytokines levels in psoriasis
by: Juanfeng Lao, et al.
Published: (2023-03-01)

The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent
by: Kylen E. Ridyard, et al.
Published: (2021-05-01)

Influence of Vitamin D Deficiency on the Level of Salivary cathelicidin LL-37 in relation to Dental Caries Experience: A Case-Control Study
by: Narjes M. Alhelfi, et al.
Published: (2023-04-01)

Sphingosine-1-Phosphate-Triggered Expression of Cathelicidin LL-37 Promotes the Growth of Human Bladder Cancer Cells
by: Tomasz Wollny, et al.
Published: (2022-07-01)

Antimicrobial peptide cathelicidin LL-37 preserves intestinal barrier and organ function in rats with heat stroke
by: Chih-Chin Shih, et al.
Published: (2023-05-01)

Structure and Activity of a Selective Antibiofilm Peptide SK-24 Derived from the NMR Structure of Human Cathelicidin LL-37
by: Yingxia Zhang, et al.
Published: (2021-11-01)

Expression and significance of serum vitamin D and LL-37 levels in infants with bacterial pneumonia
by: Shaojie Zhao, et al.
Published: (2022-11-01)

Thalidomide Attenuates Skin Lesions and Inflammation in Rosacea-Like Mice Induced by Long-Term Exposure of LL-37
by: Kang Y, et al.
Published: (2022-12-01)

Long-Term Administration of LL-37 Can Induce Irreversible Rosacea-like Lesion
by: Chuanxi Zhang, et al.
Published: (2023-03-01)

Cathelicidin (LL‐37) causes expression of inflammatory factors in coronary artery endothelial cells of Kawasaki disease by activating TLR4–NF‐κB–NLRP3 signaling
by: Feifei Si, et al.
Published: (2023-09-01)

LL-37 Triggers Antimicrobial Activity in Human Platelets
by: Francisco Javier Sánchez-Peña, et al.
Published: (2023-02-01)

Cathelicidin LL-37 promotes EMT, migration and metastasis of hepatocellular carcinoma cells in vitro and mouse model
by: Huidan Zhang, et al.
Published: (2023-12-01)

LL-37 Might Promote Local Invasion of Melanoma by Activating Melanoma Cells and Tumor-Associated Macrophages
by: Kentaro Ohuchi, et al.
Published: (2023-03-01)

Immunomodulatory Role of the Antimicrobial LL-37 Peptide in Autoimmune Diseases and Viral Infections
by: Bapi Pahar, et al.
Published: (2020-09-01)

Regulation of LL-37 in Bone and Periodontium Regeneration
by: Zahra Chinipardaz, et al.
Published: (2022-09-01)

Citrullination-Resistant LL-37 Is a Potent Antimicrobial Agent in the Inflammatory Environment High in Arginine Deiminase Activity
by: Danuta Bryzek, et al.
Published: (2020-11-01)

Nanoantibiotics containing membrane-active human cathelicidin LL-37 or synthetic ceragenins attached to the surface of magnetic nanoparticles as novel and innovative therapeutic tools: current status and potential future applications
by: Urszula Wnorowska, et al.
Published: (2020-01-01)

Cord blood antimicrobial peptide LL37 levels in preterm neonates and association with preterm complications
by: Zhuxiao Ren, et al.
Published: (2022-07-01)

Structural Plasticity of LL-37 Indicates Elaborate Functional Adaptation Mechanisms to Bacterial Target Structures
by: Kornelius Zeth, et al.
Published: (2021-05-01)

Epithelial-Immune Cell Crosstalk Determines the Activation of Immune Cells In Vitro by the Human Cathelicidin LL-37 at Low Physiological Concentrations
by: Ivan V. Bogdanov, et al.
Published: (2023-08-01)

Complexation of fungal extracellular nucleic acids by host LL-37 peptide shapes neutrophil response to Candida albicans biofilm
by: Magdalena Juszczak, et al.
Published: (2024-02-01)

The Human Antimicrobial Peptides Dermcidin and LL-37 Show Novel Distinct Pathways in Membrane Interactions
by: Kornelius Zeth, et al.
Published: (2017-11-01)

LL-37: Structures, Antimicrobial Activity, and Influence on Amyloid-Related Diseases
by: Surajit Bhattacharjya, et al.
Published: (2024-03-01)

A Simple Synthesis and Microstructure Analysis of Human Peptide LL-37@Gold Nanoparticles (Known as LL-37@AuNPs) Conjugates as Antimicrobials and Substances for Wound Healing
by: Subaer Subaer, et al.
Published: (2023-12-01)

Antifungal Activity of Human Cathelicidin LL-37, a Membrane Disrupting Peptide, by Triggering Oxidative Stress and Cell Cycle Arrest in <i>Candida auris</i>
by: Irfan A. Rather, et al.
Published: (2022-02-01)

A positive feedback loop between mTORC1 and cathelicidin promotes skin inflammation in rosacea
by: Zhili Deng, et al.
Published: (2021-05-01)

Impaired tolerance to the autoantigen LL-37 in acute coronary syndrome
by: Fernando Chernomordik, et al.
Published: (2023-03-01)

Complementary Effects of Carbamylated and Citrullinated LL37 in Autoimmunity and Inflammation in Systemic Lupus Erythematosus
by: Roberto Lande, et al.
Published: (2021-02-01)

LL-37-Coupled Porous Composite Scaffold for the Treatment of Infected Segmental Bone Defect
by: Xialin Li, et al.
Published: (2022-12-01)

Positive correlation between circulating cathelicidin antimicrobial peptide (hCAP18/LL-37) and 25-hydroxyvitamin D levels in healthy adults
by: Dixon Brian M, et al.
Published: (2012-10-01)

Insight into the Mechanism of Interactions between the LL-37 Peptide and Model Membranes of <i>Legionella gormanii</i> Bacteria
by: Katarzyna Pastuszak, et al.
Published: (2023-07-01)

Self‐assembly of PEG–PPS polymers and LL‐37 peptide nanomicelles improves the oxidative microenvironment and promotes angiogenesis to facilitate chronic wound healing
by: Rong Shi, et al.
Published: (2024-03-01)

Long-Lasting Stable Expression of Human LL-37 Antimicrobial Peptide in Transgenic Barley Plants
by: Malihe Mirzaee, et al.
Published: (2021-07-01)

Therapeutic Intervention in Cancer by Isoliquiritigenin from Licorice: A Natural Antioxidant and Redox Regulator
by: Zhu Zhang, et al.
Published: (2022-07-01)

Susceptibility of <i>Legionella gormanii</i> Membrane-Derived Phospholipids to the Peptide Action of Antimicrobial LL-37—Langmuir Monolayer Studies
by: Katarzyna Pastuszak, et al.
Published: (2024-03-01)

Cloning, Expression, and Purification of Antimicrobial Peptide LL-37 and Assessment of its Antimicrobial Effectiveness on Multiple-Drug-Resistant Acinetobacter Baumannii
by: Ehsan Zarei-Mehrvarz, et al.
Published: (2017-10-01)

LEVELS OF LL-37 ANTIMICROBIAL PEPTIDE IN THE GINGIVAL CREVICULAR FLUID OF YOUNG AND MIDDLE-AGED SUBJECTS WITH OR WITHOUT GINGIVITIS
by: Oya TÜRKOĞLU, et al.
Published: (2017-01-01)